Probiotics SB

Please note the following referenced scientific research is for informational use only. The results reported below may not necessarily occur in all our customers. The information should not replace advice from your health care practitioner. This information should not be read to recommend or endorse any specific product.

Vitable’s Probiotics SB is a blend of L. rhamnosus, B. Lactis and Saccharomyces boulardii  to support a healthy digestive system and assist with the management of digestive disturbances as well as supporting immune system function. Vitable’s probiotic contains Saccharomyces boulardii (SB) a probiotic strain that supports the establishment of friendly bacteria in the gastrointestinal system. It is a yeast (non-bacterial) probiotic that is shown to be effective when administered during the course of antibiotics and SB is not affected by the antibiotics. SB may assist with inflammatory conditions including IBS. It also works to increase gut immunity and integrity and discourages the growth of harmful microorganisms and pathogens (like that of travellers diarrhoea).

Digestive System

  • Following and during the use of antibiotics, probiotics help restore digestive balance, maintain intestinal health and replenish digestive flora.

  • Studies support specific probiotics are beneficial in lower gastrointestinal problems like intestinal gas (Hungin et al, 2018).

  • There is a strong association between probiotics and overall wellbeing with evidence associating probiotic use with a healthy digestive system function (Kechagia et al. 2013).

  • Lactobacillus rhamnosus is able to change the population of microorganisms in the gut microbiota and control the functioning of the ecosystem in the gut to support optimal function and prevent degenerative diseases  (Azad et al. 2018). 

  • Bifidobacterium species, like Lactobacillus, can inhibit harmful bacteria, improve gastrointestinal barrier function and suppress proinflammatory cytokines (Azad et al. 2018).

Traveller’s Diarrhoea

  • Evidence suggests the benefits of Saccharomyces boulardii in the treatment of diarrheal diseases caused by bacteria (Kelesidis & Pothoulakis, 2012).

Irritable Bowel Syndrome (IBS)

  • Probiotics play a role in alleviating some symptoms associated with IBS (Hoveyda et al. 2009).

  • Saccharomyces boulardii has been shown to improve IBS symptoms and quality of life in individuals with diarrhea-predominant IBS or mixed type IBS (Choi et al. 2011).

Immune System

  • Evidence indicates some probiotic strains are capable of modulating the immune system at both the systemic and mucosal levels (Braun & Cohen 2015, 773).

  • Probiotic strains including L. rhamnosus taken alongside a course of antibiotics has shown to effectively decrease the incidence of related side effects (Braun & Cohen 2015, 775).

  • Probiotics modulate the intestinal immune system by production of secreted factors and metabolites that affect the growth and function of immune cells (Hemarajata & Versalovic, 2013).

  • Probiotics exert immunomodulatory properties contributing to a fast immune response (Paineau et al. 2008).

References

  • Braun, L., and Cohen,Marc. 2015. Herbs & Natural Supplements An Evidence-based guide Volume 2. 4th ed. Australia: Elsevier.

  • Hemarajata, P., Versalovic, J. 2013. “Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation.” Therapeutic Advances in Gastroenterology, 6. (1): 39-51. 10.1177/1756283X12459294 

  • Hungin, APS., Mitchell, CR. 2018. “Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.” Alimentary Pharmacology & Therapeutics, 47. 8 (Apr): 1054-1070. doi:10.1111/apt.14539

  • Kechagia, M., Basoulis, D., Konstantopoulou, S., Dimitriadi, D., Gyftopoilou, K., Sharkmoutsoi, N., Fakiri, EM. 2013. “Health benefits of probiotics: a review”. ISRN Nutrition, 2013. 10.5402/2013/481651

  • Azad, M., Sarker, M., Li, T., Yin, J., 2018. “Probiotic species in the modulation of gut microbiota: AN overview.” BioMed Research International, 9478630. 10.1155/2018/9478630

  • Paineau, D., Carcano, D., Leyer, G., Darquy, S., Alyanakian, MA., Simoneau, G., Bergmann, JF.,Brassart, D., Bornet, F., Ouwehand, AC. 2009. “Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial”. FEMS Immunology & Medical Microbiology, 53. 1 (Jun): 107–113. https://doi.org/10.1111/j.1574-695X.2008.00413.x

  • Kelesidis, T., Pothoulakis., C. 2012. “Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders”. Therapeutic advances in gastroenterology, 5. 2 (Mar): 111–125. https://doi.org/10.1177/1756283X11428502'

  • Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., Glasziou, P. 2009. “A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome”. BMC gastroenterology, 9.15 (Feb). https://doi.org/10.1186/1471-230X-9-15

  • Choi, C. H., Jo, S. Y., Park, H. J., Chang, S. K., Byeon, J. S., & Myung, S. J. 2011. “A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life”. Journal of clinical gastroenterology, 45. 8 (Sep): 679–683. https://doi.org/10.1097/MCG.0b013e318204593e

  • Vandenplas, Y. 1999. “Bacteria and yeasts in the treatment of acute and chronic infectious diarrhea. Part II: Yeasts”. Clinical Microbiology and Infection, 5. 7 (July): 398-395. https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)63754-X/fulltext#seccestitle190